恩替卡韦联合胸腺肽α1治疗HBeAg阳性慢性乙型肝炎疗效

Efficacy of combined use of entecavir and thymosin α1 in treating HBeAg-positive chronic hepatitis B

目的探讨恩替卡韦联合胸腺肽α1治疗HBeAg阳性慢性乙型肝炎(CHB)的疗效。方法 HBeAg阳性的CHB患者120例随机分为两组,在内科综合治疗基础上分别加用胸腺肽α1皮下注射,1.6mg/次,2次/周和恩替卡韦0.5mg/d(A组,66例)和单独恩替卡韦(B组,54例)。两组均连续用药48周。结果 A组HBeAg转阴率为57.58%,HBeAg/抗-HBe转换率为34.85%,均高于B组的24.07%和11.11%(P<0.05);A组肝纤维化指标透明质酸酶、层黏连蛋白、Ⅳ型胶原和Ⅲ型前胶原下降幅度较B组更为显著(P<0.05)。结论恩替卡韦联合胸腺肽α1治疗HBeAg阳性CHB患者可提高HBeAg转阴率和HBeAg/抗-HBe转换率,改善CHB患者肝纤维化指标。

Objective To investigate the efficacy of combined use of entecavir and thymosin al in treating HBeAg-positive chronic hepatitis B（CHB）. Methods A total of 120 HBeAg-positive CHB patients was assigned into two groups. On the basis of conventional therapy, group A（66 cases） was treaed with additional entecavir 0. 5 rng once a day and thymosin αl 1.6 mg, subcutaneously twice a week and group B（54 cases） was given additional entecavir only. The treatment lasted for 48 weeks. Results The negative conversion rate of HBeAg and HBeAg/anti-HBe conversion rate in group A were 57.58% and 34. 85%, respectively, which were higher than 24. 07% and 11.11% in group B （P〈0. 05）. The decreases in hepatic fibrosis indicators （hyaluronidase, laminin, collagen IV and precollagen Ⅲ ） were more in group A than those in group B（P〈0. 05）. Conclusion Combined use of entecavir and thymosin α1 may effectively increase the negative conversion rate of HBeAg and HBeAg/anti-HBe conversion rate and improve the hepatic fibrosis indicators in patients with HBeAg- oositive CHB.